Skip to Content
  • Eribulin Gets Reviewed, Finally

    So it looks like the FDA is giving reviewing Eisai’s oncology drug Eribulin (E7389) a priority review. The company had hoped to get it reviewed three year… Read More
  • Environmental Cancer?

    I find the President’s Cancer Panel report -at least, the general tone of it – hard to believe. Most of the headlines yesterday focused on the ̶… Read More
  • Intermune: Right Back Down Again

    Back in March, Intermune’s stock saw a sudden jump on news that an FDA advisory committee treated their drug pirfenidone more positively than expected. Bu… Read More
  • Garage Biotech

    Freeman Dyson has written about his belief that molecular biology is becoming a field where even basement tinkerers can accomplish things. Whether we’re r… Read More
  • Intermune’s Rise

    If you want to know why people continue to speculate in biotech stocks, just take a look at the stairsteppy last few days of trading in Intermune (ITMN). Last T… Read More
  • Vaccines in the Court

    The Supreme Court has agreed to hear a vaccine-liability case, in an attempt to untangle conflicting lower court rulings. This all turns on the 1986 act that sh… Read More
Page 20 of 24« First...10...1819202122...Last »